Compare
Revolution Medicines, Inc. vs Amgen Inc vs Repligen Corp vs Bio-Techne Corp
| Latest fiscal year | Revolution Medicines, Inc. RVMD | Amgen Inc AMGN | Repligen Corp RGEN | Bio-Techne Corp TECH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $0 | $36.75B | $738.26M | $1.22B |
| Revenue growth (YoY) | n/a | +10.0% | +16.4% | -0.4% |
| Gross margin | n/a | 67.2% (computed) | 52.3% (computed) | 65.8% |
| Operating margin | n/a | 24.7% | 7.5% | 20.7% |
| Net margin | n/a | 21.0% | 6.6% | 15.0% |
| Net income | -$1.13B | $7.71B | $48.89M | $181.86M |
| EPS (Diluted) | -$5.95 | $14.23 | $0.86 | $1.16 |
| Operating cash flow | -$897.74M | $9.96B | $117.42M | $292.07M |
| Free cash flow | -$913.73M | $8.10B | $93.90M | $263.22M |
| Cash & equivalents | $383.75M | $9.13B | $566.02M | $264.71M |
| Total assets | $2.35B | $90.59B | $2.95B | $2.59B |
| Total liabilities | $723.21M | n/a | $843.57M | n/a |
| Shareholders' equity | $1.63B | $8.66B | $2.11B | $2.11B |
| Return on year-end equity | -69.3% | 89.1% | 2.3% | 8.6% |
| Shares outstanding | 197.00M | 538.80M | 56.33M | 156.10M |
Revenue, most recent five fiscal years
| Fiscal year | Revolution Medicines, Inc. | Amgen Inc | Repligen Corp | Bio-Techne Corp |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $1.22B Ended 2026-06-30 |
| 1 year earlier | $0 Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $1.22B Ended 2025-06-30 |
| 2 years earlier | $11.58M Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $1.16B Ended 2024-06-30 |
| 3 years earlier | $35.38M Ended 2022-12-31 | $26.32B Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $1.14B Ended 2023-06-30 |
| 4 years earlier | $29.39M Ended 2021-12-31 | $25.98B Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $1.11B Ended 2022-06-30 |